Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC)

Urologic Oncology: Seminars and Original Investigations

Volumn 31, Issue 3, 2013, Pages 379-385

  Harshman, Lauren C ^a   Yu, R James ^a   Allen, Genevera I ^b   Srinivas, Sandy ^a   Gill, Harcharan S ^a   Chung, Benjamin I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Rice University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; SORAFENIB; SUNITINIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER SIZE; CASE CONTROL STUDY; CASE STUDY; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; FEMALE; HUMAN; INCISIONAL HERNIA; KIDNEY CARCINOMA; KIDNEY SIZE; MALE; METASTASIS RESECTION; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION; WOUND HEALING IMPAIRMENT;

AGED; CARCINOMA, RENAL CELL; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEPHRECTOMY; NIACINAMIDE; PHENYLUREA COMPOUNDS; POSTOPERATIVE COMPLICATIONS; PREOPERATIVE CARE; PROTEIN KINASE INHIBITORS; PYRROLES; TREATMENT OUTCOME; URINARY BLADDER;

EID: 84875380717     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2011.01.005     Document Type: Article

References (25)

1. Kondo K., Yao M., Yoshida M., et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: Relationship to clinicopathologic parameters. Genes Chromosomes Cancer 2002, 34:58-68.
2. Sukosd F., Kuroda N., Beothe T., et al. Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma. Cancer Res 2003, 63:455-457.
3. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
4. Gore M.E., Szczylik C., Porta C., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: An expanded-access trial. Lancet Oncol 2009, 10:757-763.
5. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon &;α in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
6. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295:2516-2524.
7. Stadler W.M., Figlin R.A., McDermott D.F., et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010, 116:1272-1280.
8. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
9. Amin C., Wallen E., Pruthi R.S., et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 2008, 72:864-868.
10. Cowey CL, Amin C, Pruthi RS, et al. Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma. J Clin Oncol 1502, 28:1502-7.
11. Harshman L.C., Srinivas S., Kamaya A., et al. Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib. Nat Rev Urol 2009, 6:338-343.
12. Jonasch E., Wood C.G., Matin S.F., et al. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:27.
13. Margulis V., Matin S.F., Tannir N., et al. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 2008, 180:94-98.
14. Neill M.G., Wei A.C., Jewett M.A. Consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy. Urology 2007, 70:178. e179-111.
15. Rini BI. Tyrosine-kinase inhibitors in a presurgical setting. Proceedings of the 2009 American Society of Clinical Oncology's Genitourinary Cancers Symposium, Orlando, FL.
16. Rini B.I., Campbell S.C. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J Urol 2007, 177:1978-1984.
17. Shuch B., Riggs S.B., LaRochelle J.C., et al. Neoadjuvant targeted therapy and advanced kidney cancer: Observations and implications for a new treatment paradigm. BJU Int 2008, 102:692-696.
18. Thomas A.A., Rini B.I., Lane B.R., et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 2009, 181:518-523. Discussion 523.
19. Thomas A.A., Rini B.I., Stephenson A.J., et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009, 16:16.
20. van der Veldt A.A., Meijerink M.R., van den Eertwegh A.J., et al. Sunitinib for treatment of advanced renal cell cancer: Primary tumor response. Clin Cancer Res 2008, 14:2431-2436.
21. Wood C.G., Margulis V. Neoadjuvant (presurgical) therapy for renal cell carcinoma: A new treatment paradigm for locally advanced and metastatic disease. Cancer 2009, 115(10 Suppl):2355-2360.
22. Pattaras J.G., Moore R.G., Landman J., et al. Incidence of postoperative adhesion formation after transperitoneal genitourinary laparoscopic surgery. Urology 2002, 59:37-41.
23. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
24. Sorafenib package insert 2009, Bayer Pharmaceutical Co.
25. Sunitinib maleate package insert 2010, Pfizer.